# Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma

> **NCT01636388** · PHASE2 · TERMINATED · sponsor: **New York Medical College** · enrollment: 2 (actual)

## Conditions studied

- Hodgkins Lymphoma

## Interventions

- **BIOLOGICAL:** allogeneic donor derived LMP specific cytotoxic T-lymphocyte

## Key facts

- **NCT ID:** NCT01636388
- **Lead sponsor:** New York Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01
- **Primary completion:** 2017-06
- **Final completion:** 2017-12
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** funding ended
- **Last updated:** 2017-12-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01636388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01636388, "Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01636388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*